U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06908694) titled 'Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy' on March 26.
Brief Summary: GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: Semaglutide Pen Injector
The semaglutide dose will be 0.25mg subcutaneously once weekly for weeks 1-4, then 0.5mg once weekly for weeks 5-8, then 1mg once weekly for weeks 9-12, then 1.7mg once weekly for weeks 13-16, and then 2.4m...